C4 Therapeutics, Inc. (NASDAQ: CCCC)

C4 Therapeutics is a clinical-stage biopharmaceutical company focused on advancing targeted protein degradation, or TPD, science to create a new generation of small-molecule medicines. Leveraging its proprietary TORPEDO platform, the company designs and optimizes oral bioavailable protein degraders that harness the cell’s natural ubiquitin-proteasome system to eliminate disease-causing proteins. Its pipeline includes oncology candidates for multiple myeloma and non-small cell lung cancer, as well as early-stage programs targeting inflammation, neuroinflammation and neurodegeneration.

C4 Therapeutics generates revenue primarily through collaboration and licensing agreements with pharmaceutical partners. These arrangements provide upfront cash payments, research funding, milestone payments tied to development, regulatory and sales achievements, and tiered royalties on net sales of any resulting products. Current collaborations include agreements with Pfizer for clinical trial supply, Merck KGaA for oncology target discovery, Roche for various target programs, Betta Pharma for development of an EGFR degrader in Greater China, and Biogen for immunology-related degrader programs. The company has not yet commercialized any product and therefore does not derive revenue from product sales.

• no_segments_reported.

Within the emerging targeted protein degradation sector, C4 Therapeutics competes with other biotechnology firms such as Arvinas and several academic and pharmaceutical entities pursuing similar modalities. Its competitive advantage lies in the TORPEDO platform, which enables rational design of degraders with desired properties including oral bioavailability, blood-brain barrier penetration and catalytic activity. The platform’s focus on the Cereblon E3 ligase, supported by a proprietary library of Cereblon binders, aims to improve degrader efficiency and selectivity compared to traditional inhibitors. Additionally, the company’s ability to advance both mono‑ and bis‑specific degraders expands its target range beyond that achievable with conventional small‑molecule approaches.

The company’s prospective customers are patients suffering from relapsed or refractory multiple myeloma, non-small cell lung cancer with EGFR mutations, and individuals with inflammatory, neuroinflammatory or neurodegenerative disorders. Until therapies receive regulatory approval, C4 Therapeutics works closely with collaboration partners such as Pfizer, Merck KGaA, Roche, Betta Pharma and Biogen, who fund research and development efforts and may eventually commercialize the resulting medicines in their respective territories.